One-year-old boy spoke his first words hours before he was killed by Israeli strike in Gaza
Ten children were killed while they and their mothers were waiting to receive nutritional supplements from UNICEF's Project Hope in Deir el-Balah.
UNICEF's executive director Catherine Russell said the mothers were seeking 'a lifeline for their children after months of hunger and desperation'.
Among them was Donia, whose 1-year-old boy Mohammed was killed in the strike.
'She said he spoke his first words to her just hours earlier,' Russell said.
'Donia now lies in a hospital bed, critically injured by the blast, clutching Mohammed's tiny shoe. No parent should have to face such tragedy.'
Russell said this was another example of the 'cruel reality' of life for children and families in Gaza.
'The killing of families trying to access life-saving aid is unconscionable,' she added.
Sara Al-Nouri mourns over the body of her 13-year-old sister, Sama, who was killed in the strike at the Project Hope clinic
Alamy Stock Photo
Alamy Stock Photo
The US-based charity Project Hope, which runs the facility, said the victims were waiting for the clinic to open to receive treatment for malnutrition, infections and illness. The charity gave a toll of 15 dead, including 10 children and two women.
Its president and chief executive Rabih Torbay called the strike 'a blatant violation of international humanitarian law.'
Yousef Al-Aydi, 30, was among dozens of people – most of them women and children – in the queue.
'Suddenly, we heard the sound of a drone approaching, and then the explosion happened,' he told the AFP news agency by phone.
'The ground shook beneath our feet, and everything around us turned into blood and deafening screams.'
Israel has expanded its military operations in Gaza, where the war has created dire humanitarian conditions for the population of more than two million people.
Advertisement
The Israeli military told AFP that it targeted a Hamas militant in Deir el-Balah who had infiltrated Israel during the group's 7 October 2023 attack.
It said it 'regrets any harm to uninvolved individuals and operates to minimise harm as much as possible', adding the incident was under review.
'Killed instantly'
Mohammed Abu Ouda, 35, was also in the queue at Project Hope. 'What was our fault? What was the fault of the children?' he asked.
'I saw a mother hugging her child on the ground, both motionless – they were killed instantly.'
AFP was unable to independently verify the tolls and details because Israel does not allow media access to Gaza.
Four people were killed and several injured in a separate pre-dawn air strike on a home in Al-Bureij camp in central Gaza, civil defence agency official Mohammed al-Mughair added.
AFP footage from Al-Bureij showed a family including three young children sitting among rubble outside their tattered tent after an air strike hit a house next door.
Elsewhere, three people, including a woman, were killed by Israeli gunfire on civilians near an aid centre in the southern city of Rafah, the civil defence agency said.
More than 600 people have been killed around aid distributions and convoys in Gaza since late May, when Israel began allowing a trickle of supplies, the United Nations said in early July.
The European Union said it had struck a deal with Israel to open more crossings for aid, as well as to repair infrastructure and protect aid workers.
The war began after Hamas attacked Israel on October 7, 2023, leading to the deaths of 1,219 people, most of them civilians, according to an AFP tally of official Israeli figures.
Israel's war on Gaza has now killed at least 57,762 people, most of them civilians, according to the territory's health ministry.
With reporting from AFP
Need more information on what is happening in Israel and Palestine? Check out our FactCheck Knowledge Bank for essential reads and guides to navigating the news online.
Visit Knowledge Bank
Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article.
Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.
Learn More
Support The Journal
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Examiner
13 hours ago
- Irish Examiner
Glanbia upgrades full-year outlook on strong performances of dairy and health segments
Irish food giant Glanbia upgraded its full-year guidance for 2025 on the back of strong results for the first half of the year, with revenues rising 6% to $1.93bn (€1.7bn) driven by growth in its Health & Nutrition (H&N) and Dairy Nutrition (DN) divisions. The Kilkenny firm, which separated from the farmer-owned co-op Tirlán to focus on its global business, increased its interim dividend by 10% to 17.20 cent per share and returned €62.8m to shareholders via share buyback programs. Glanbia's Health & Nutrition division, which creates flavourings and ingredients for other companies, saw an 18% revenue increase, driven by a 6.9% rise in volume and a significant 11.5% contribution from acquisition. Glanbia announced the acquisition of Sweetmix, a Brazil-based nutritional solutions business, to facilitate growth in the Latin American market. The Dairy Nutrition segment delivered a 14.1% increase in revenue. This was driven by a combination of volume growth and favourable dairy market pricing. Glanbia CEO Hugh McGuire. However, the company's Performance Nutrition (PN) division faced challenges, with a 3.8% decline in revenue. This was primarily attributed to elevated whey protein costs and anticipated declines in non-core brands. However, Glanbia said there were positive signs of recovery, particularly with the flagship Optimum Nutrition brand, which saw a revenue increase in the second quarter. CEO Hugh McGuire said: 'Today's results reflect a first half of significant execution and progress as we generated 6% revenue growth in the period, underpinned by strong growth in H&N and DN and a sequential improvement in PN through the period as the Group navigated significant macroeconomic volatility.' Glanbia announced the appointment of Paul Duffy as Chair-Designate, who will succeed Donard Gaynor on January 1.
RTÉ News
13 hours ago
- RTÉ News
Glanbia raises full year earnings guidance, names new chairman
Shares in nutrition supplement maker Glanbia jumped 12% in early trade in Dublin today after it increased its full-year earnings outlook and said it was overcoming challenges that pushed its shares to a two-year low in February. Glanbia also said today that its independent non-executive director Paul Duffy will succeed Donard Gaynor as Chair of the Company on January 1, 2026. In its results statement today, Glanbia said it expected full-year earnings per share of $1.30-$1.33 on an adjusted basis, up from its previous forecast of $1.24-$1.30. The firm earned $1.40 per share last year. The US-focused company reported "strong growth" in its Health & Nutrition and Dairy Nutrition businesses and "sequential improvement" in Performance Nutrition. The company is not seeing any consumer weakness in the US and the impact of tariffs is "manageable", its chief financial officer Mark Garvey said after the release of the results. "You never know with today's market when you are, but certainly I feel a lot better than I did three months ago," Mr Garvey said. Glanbia in February issued a profit warning, in part due to a rise in the cost of whey - a key ingredient in the protein powders and shakes popular with gym goers. Whey prices now look likely to moderate next year as more capacity comes on stream, Garvey said. The firm in April reported lower revenue from performance nutrition products in US club retailers and speciality channels, but in the second quarter of the year saw positive volumes and pricing through those channels, Garvey said. "We're going to pass that club channel challenge that we had," Mr Garvey said. Glanbia said that group revenues for the six months to July 5 increased by 6% to $1.93 billion from $1.82 billion the same time last year, mainly down to price increases and the impact of acquisitions. But its group EBITDA, before exceptionals, fell by 7.5% to $241.3m from $261.6m, while its adjusted earnings per share of 63.03 cent was also 7.5% lower on the figure of 68.20 cent reported last year. The company said it was making good progress on its transformation programme, targeting annual savings of at least $50m a year by 2027. It said its board is recommending an interim dividend of 17.20 cent per share, a 10% hike of the interim dividend of 15.64 cent per share last year. Hugh McGuire, Glanbia's chief executive, said the results reflect a first half of significant execution and progress as it generated 6% revenue growth, underpinned by strong growth in the Health & Nutrition and Diary Nutrition divisions and a sequential improvement in its Performance Nutrition division as it navigated "significant macroeconomic volatility". "First half results were driven by volume growth, earnings and margin progression in H&N and DN, reflecting strong customer demand. This was offset by anticipated reduced performance in PN primarily as a result of elevated whey costs during the period," Mr McGuire said. "We delivered strong operating returns and cash conversion and continue to have a disciplined approach to capital allocation, with a 10% increase in the interim dividend and €62.8 million returned to shareholders via share buyback programmes during the period," the CEO said. "We are today upgrading our full year adjusted EPS guidance to 130 to 133 cent as a result of increased revenue momentum in PN and improved margins in H&N. The category trends remain positive, and we expect to see continued improvement in volumes across PN in the second half of the year with continued momentum in H&N and DN," he added, The company today also announced a deal to acquire Sweetmix, a Brazil-based nutritional premix and ingredients solutions business, which it said will facilitate continued growth in the Latin America region. Glanbia names Duffy as new chairman Meanwhile, the company also said today that its independent non-executive director Paul Duffy will succeed Donard Gaynor as Chair next year. Mr Gaynor will retire as Chair and from the Board of the company on December 31. Mr Duffy has been a director of Glanbia since March 2021 and has significant global business experience in the consumer sector. He is a member of the company's nomination & Governance and Remuneration Committees as well as Chair of the Audit Committee. He is a former Chairman and CEO of Pernod Ricard North America and during his 25 year career with Pernod Ricard, Paul held a number of senior leadership positions including serving as Chairman and CEO roles at Pernod Ricard UK, The Absolut Company (Sweden) and Irish Distillers. Paul is a Fellow of Chartered Accountants Ireland and is a graduate of Trinity College Dublin, Ireland. He is a Non-Executive Director of Hostelworld, WA Baxter & Sons and former Chairman of Irish Children's Museum. Breaking down its divisions, Glanbia said that revenues at its Performance Nutrition unit fell by 3.6% to $850m from $882.1, while EBITDA dropped by 30.8% to $108.2m from $156.4m with the decline mainly due to anticipated challenges in the US club and speciality channels and declines in non-core brands. It noted that price increases that were implemented across international markets during the first quarter of the year were offset by some tactical price reductions on specific products globally. Revenues at its Health & Nutrition division rose by 18.4% to $313m from $264.3m and EBITDA jumped by 36.2% to $60.9m from $44.7m the same time last year, driven by a 6.9% increase in volume and an 11.5% increase from the impact of acquisitions. Meanwhile, revenues at its Dairy Nutrition division rose by 14.1% to $763.7m from $669.2m while EBITDA rose by 19.3% to $72.2m from $60.5m on the back of a 4.3% increase in volume and a 9.8% increase in price driven by favourable dairy markets and strong whey protein demand.
The Journal
a day ago
- The Journal
The millionaire millennial seeking the presidency: How did Gareth Sheridan get so rich?
BUSINESSMAN GARETH SHERIDAN is seeking to become the youngest-ever Irish presidential candidate during this year's election, and claims to have secured support to make that possible. Much of the Irish public were introduced to 35-year-old Sheridan for the first time this week as a millionaire, pharmaceutical tycoon who recently returned to Ireland having spent the last seven years building up his company in the US. But how, exactly, did he earn his millions? And what does his company do? Acquisitions and mergers Nurtiband, a US-based healthcare-led company valued at approximately $80m, was started by Sheridan in 2012, during his final year at DIT in Dublin, where he was studying businesses and management. Taking inspiration from a transdermal patch his father had for a heart condition, Sheridan wrote his undergraduate thesis on providing properly-dosed medicine to patients through more accessible means, like patches, which are less likely to abuse. Early social media posts from Sheridan show that the company began by selling supplements, such as energy and metabolism-boosting patches, but the Dubliner wanted to branch out into the opioid market. Former Áras contender Seán Gallagher was later enlisted as the company's President (he has since left and has no current relationship with Sheridan) as the CEO worked towards getting the company listed on the Nasdaq stock exchange. Nutriband's strategy focused on carrying out a number of mergers and acquisitions, purchasing companies through its own stock options as a private company, over the last ten years, Sheridan explained on The Entrepreneur Experiment podcast in April. Sheridan focused on merging with firms with existing specialities in pharmaceuticals and biotechnology. It listed on the New York-based stock exchanged in October 2023, generating over $6m on its first day. Nutriband has now focused wholly on opioids through transdermal patches – similar to products used for nicotine-replacement therapy. Opioids, a type of pain-relief medication, have proven to be addictive among some patients. While they are an effective method to treat chronic pain, doctors – particularly in the US – have been reluctant to prescribe the medicines. Image posted by Sheridan in 2023 after his company was listed on the Nasdaq stock exchange in New York. Gareth Sheridan Gareth Sheridan As a result, more people have sought to purchase opioids illegally, and the black market drugs trade responded by introducing potent or synthetic alternatives over the last decade. The most-famous of these in the US is fentanyl, currently. Sheridan said that the most-important of Nutriband's acquisitions was the purchase of 4P Therapeutics in 2018, a company from two pharma veterans who created AVERSA technology , which prevents the misuse of opioids. It is today his lead product. During one acquisition, Nutriband pulled out of purchasing the manufacturer of transdermal patches . It was subsequently reported that a lawyer representing the firm did not disclose their ownership position in both companies. Asked about this on RTÉ Radio One yesterday, Sheridan explained that it was the only time that his firm had faced any trouble with US authorities and that, for Nutriband, it was seen as a minor issue and required the firm to correct submitted paperwork. Advertisement Unique selling point Sheridan has said he wants Nutriband to benefit those who are ill, developing patches that provide patients with a safe dose of medicines that are commonly abused – primarily opioids – targeting those who are in need of the controversial medicines. If abused, the drugs can cause long-term health complications, impact organ health and – in the case of synthetic and potent alternatives especially – minor doses can result in death. We're up and running! Excited to have announced my intention to seek a nomination for the upcoming Presidential election. I look forward to setting out my values and vision for the Presidency over the coming days and continuing to engage with Councillors across the country. — Gareth Sheridan (@GPSheridan1) August 11, 2025 Sheridan's business case is that there are still many people, in the US particularly, who need these pain medicines for proper health-related reasons. He believes the managed doses from his firm's patches is a unique selling point and a prevention of abuse and addiction. He said that there's been an increase of American patients being told to use over-the-counter pain medication for illnesses, and claims his patches could be a safer and more appropriate option. Pharmaceutical patches Sheridan in April said acquisitions and mergers were 'the strategy' for the company. Some of the previous owners from the purchased companies went on to join Sheridan and held positions at Nutriband for a short time. He explained, due to his own lack of expertise in pharmacology, he needed those who could help actually develop his ideas. He added: 'It also kept us away from expensive money. I am able to retain today a good proportion of the company because we didn't do angel [investor] rounds, seed rounds. We didn't do the traditional route.' News reports of the company's activities recently have focused on its newest patch, which would deliver a proper prescribed dose of fentanyl . The firm is still in ongoing discussions with the US's drugs regulator, the Food and Drug Administration. In preparation for its approval, it has offered shareholders particular stock options to raise funds. Success? Nutriband is yet to generate any revenue. In its most-recent public quarterly report, at the end of October last year, it recorded a net-loss of $1.3m. Speaking to The Entrepreneur Experiment in April, Sheridan said: 'In most public companies it's either one person makes a million dollars or, years later, dozens of people make multiple millions of dollars. So there's patience and trust involved.' The Áras hopeful, who has stepped back as CEO from Nutriband to pursuit the election later this year, said he is certain the company will be worth a billion dollars in the future. Sheridan said the firm has been careful not to waste any funding too: 'We've been very careful not to raise money that we don't need – money that is sitting in a bank account at the expense of shareholders [...] It's just little things like that.' He told RTÉ Radio One yesterday that he believes Nutriband will still achieve that goal, with or without him. He said that he intends to have a stake in the firm, should he be placed on the ballot and elected President. Sheridan said he is seeking to be nominated as a candidate to represent the interests of young people who feel that they must emigrate for work and other opportunities due to the housing situation here. He is due to announced his platform's values later this week. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
